Safety and Effectiveness of Adjunctive Intra-Arterial Abciximab in the Management of Acute Limb Ischemia

Contemporary endovascular management of acute limb ischemia (ALI) generally consists of tissue plasminogen activator (tPA) based catheter-directed thrombolysis (CDT) with or without pharmacomechanical thrombectomy (PMT). Although abciximab (Reopro), a GPIIb/IIIa receptor antagonist, is widely used in coronary revascularization, its safety and effectiveness in the treatment of ALI are unknown. Here, we review our contemporary experience with the endovascular management of ALI and assess the safety and effectiveness of abciximab.

Source: Annals of Vascular Surgery - October 14, 2015 Category: Surgery Authors: Gregory G. Salzler, Ashley Graham, Peter H. Connolly, Darren B. Schneider, Andrew J. Meltzer Tags: Vascular & Endovascular Surgery Society Source Type: research